AI Article Synopsis
- Liver transplantation is often the only treatment option for patients with severe liver failure due to Wilson's disease when drugs don't work.
- A case was reported of a 29-year-old woman who developed neurological issues after her liver transplant and was diagnosed with moyamoya disease.
- Moyamoya disease is a rare condition related to brain blood vessels, and while its cause is unknown, some immunosuppressive treatments may contribute to its development, making this connection noteworthy post-transplant for Wilson's disease.
Article Abstract
In Wilson's disease, liver transplantation can constitute the only option for patients presenting with fulminant hepatic failure or decompensated liver disease unresponsive to drug therapy. We report the case of a 29-year-old woman receiving a liver transplant for end-stage Wilson's disease who developed neurological complications after transplantation. After an accurate evaluation of possible differential causes of neurological complications developing as the result of liver transplantation, moyamoya disease was diagnosed. Moyamoya disease is a rare cerebrovascular disease of unknown etiology. However, data exist supporting a possible role for some immunosuppressive regimens in determining the peculiar vascular alterations observed in moyamoya disease. To the best of our knowledge, the association with post-transplantation state for Wilson's disease has not been previously described.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1872-034X.2010.00764.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: RING finger protein 213 () p.R4810K is an established risk factor for moyamoya disease and intracranial artery stenosis in East Asian people. Recent evidence suggests its potential association with extracranial cardiovascular diseases, including pulmonary hypertension.
View Article and Find Full Text PDFCorrigendum: Case Report: A rare presentation of rapidly progressive moyamoya disease refractory to unilateral surgical revascularization.
Front Surg
January 2025
Cerebrovascular and Endovascular Neurosurgery, Southeast Health, Dothan, AL, United States.
[This corrects the article DOI: 10.3389/fsurg.2024.
View Article and Find Full Text PDFSystemic Immune-inflammation Index Is Associated with Symptomatic Cerebral Hyperperfusion after Revascularization Surgery in Moyamoya Disease.
Neurol Med Chir (Tokyo)
January 2025
Department of Neurosurgery, Hokkaido University Graduate School of Medicine.
Revascularization surgery for moyamoya disease poses risks of complications, requiring appropriate management. Although precise prediction is difficult, the systemic immune-inflammation index is a calculable marker that reflects systemic inflammatory conditions. We aimed to investigate the association between postoperative complications and the systemic immune-inflammation index.
View Article and Find Full Text PDFIntraoperative Superficial Temporal Artery-middle Cerebral Artery Bypass Failure during Combined Bypass Surgery in Children with Moyamoya Disease.
Neurol Med Chir (Tokyo)
January 2025
Department of Neurosurgery, Tohoku University Graduate School of Medicine.
Pediatric patients with moyamoya disease frequently show rapid progression with a high risk of stroke. Indirect revascularization is widely accepted as a surgical treatment for pediatric moyamoya disease, but it does not augment cerebral blood flow immediately, which leaves patients at risk for stroke peri-operatively. This delay in flow augmentation may make adding direct bypass the better option.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!